What are ASCO recommendations for second-line therapy for stage IV non–small cell lung cancer (NSCLC) in patients with sensitizing endothelial growth factor receptor (EGFR) mutation?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with a sensitizing EGFR mutation who experienced disease progression with a first-line EGFR tyrosine kinase inhibitor (TKI) recommendations include the following:

  • If the T790M resistance mutation is present, recommend osimertinib
  • If the T790M mutation is not present, clinicians offer treatment with a platinum-based doublet
  • If the patient had an initial response to first-line treatment but then experienced slow or minimal disease progression at isolated sites, EGFR TKI treatment can be continued, with local therapy to the isolated sites

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!